Bayer Completes Capital Injection Into Topsun
This article was originally published in PharmAsia News
Executive Summary
Bayer has completed its capital injection of 1.264 billion yuan ($180 million) into Topsun Science & Technology's subsidiary Qidong Gaitianli Medicine, known for its popular OTC cold and cough products. The deal transfers to Bayer all Gaitianli's products, manufacturing facilities and sales networks in China. At the same time, Topsun has begun to settle its debts, reassign markets and clear assets. According to Topsun's 2007 annual report, its sale of Gaitianli brings much-needed cashflow to pay off debts and ease other capital pressures. (Click here for more - Chinese language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.